BioPharmaPT
← All reports

NEUROCRINE — Ingrezza FDA Review (NDA/BLA 209241, 2022)

NEUROCRINE · 2022 · FDA Review (Drugs@FDA) · company profile →

Report summary

This report summarizes the FDA approval of Neurocrine Biosciences' Ingrezza (valbenazine) for adult tardive dyskinesia. It details the drug's indication, dosage, administration, warnings, precautions, and drug interactions, particularly for patients with hepatic impairment, CYP2D6 poor metabolizers, and those on strong CYP3A4 or CYP2D6 inhibitors. Clinical pharmacology findings addressed post-marketing commitments, revealing a significant increase in the active metabolite NBI-98782 with strong CYP2D6 inhibitors, necessitating a dose reduction. Severe renal impairment had no clinically meaningful impact. Labeling negotiations, finalized by March 31, 2020, incorporated these findings, especially regarding dosage recommendations for CYP2D6 poor metabolizers and drug interactions.

Key findings — cited to the page

Headache incidence (INGREZZA)3.4 %INGREZZA · p.12
Indicationtreatment of adults with tardive dyskinesia INGREZZA (valbenazine) · p.1
Approval DateApril 09, 2020 INGREZZA (valbenazine) · p.1
Revision Date04/2020 · p.9
Initial dosage40 mg once dailyINGREZZA · p.9
Recommended dosage80 mg once dailyINGREZZA · p.9
Recommended dosage for moderate or severe hepatic impairment40 mg once dailyINGREZZA · p.9
Recommended dosage for known CYP2D6 poor metabolizers40 mg once dailyINGREZZA · p.9
Initial dosage40 mg once dailyINGREZZA · p.10
Recommended dosage80 mg once dailyINGREZZA · p.10
Recommended dosage for moderate or severe hepatic impairment40 mg once dailyINGREZZA · p.10
Recommended dosage for known CYP2D6 poor metabolizers40 mg once dailyINGREZZA · p.10

Source: NEUROCRINE · License: US Government public domain. Summary and findings are extracted from the published document; every figure cites its page. Informational only — not investment advice. Explore the Neurology library →

NEUROCRINE — Ingrezza FDA Review (NDA/BLA 209241, 2022) — Summary & Key Findings | BioPharmaPT